ArriVent Reports 44.8% Objective Response in Colorectal Cancer

ArriVent reported encouraging initial Phase 1 results for ARR-217 (MRG007), its CDH17-targeting antibody-drug conjugate being studied in heavily pretreated patients with gastrointestinal cancers. The company reported a 44.8% objective response rate among late-line colorectal cancer patients and described the safety profile as manageable. The findings were presented at the 2026 ESMO Congress, and ArriVent plans to advance the drug into a Phase 1b dose-optimization study, with further data expected in 2027.





